Management

This page includes content on healthcare management, including health system, hospital, department and clinic business management and administration. Areas of focus are on cardiology and radiology department business administration. Subcategories covered in this section include healthcare economics, reimbursement, leadership, mergers and acquisitions, policy and regulations, practice management, quality, staffing, and supply chain.

Health Affairs: Registries promote better care, U.S. needs to get up to speed

As healthcare costs increase around the world, many countries are beginning to rely on disease registries, which can produce substantial savings. An international study of 13 registries in five countries (Australia, Denmark, Sweden, the U.K. and the U.S.) found that registries enable healthcare professionals to engage in continuous learning as well as identify and share best clinical practices.

N.Y. stakeholders recommend statewide healthcare changes

A workgroup comprised of various stakeholders in the New York state healthcare system composed a list of payment reform and quality measurement recommendations for the New York State Department of Health to consider as the state transitions to Medicaid payment models based on quality of care.

Take the CMIO salary survey; win a $100 gift card

It's time for the annual CMIO Compensation Survey. CMIOs and other health IT leaders are invited to help CMIO compile a comprehensive view of the trends in the industry and the factors that are most important when determining salary. Three participants will win a $100 Visa gift card.

Leapfrog highlights 2011 top hospitals, with lots of Kaiser love

Its that time of year when hospitals find out who provided healthcare services worthy of The Leapfrog Group's 2011 Top Hospital list. The 11th annual survey has given 65 hospitals Top Hospital designations, based on their ability to reduce medical errors, readmissions and mortality and gives particular credence to the California Kaiser facilities.

Feature: With Stage 2 on horizon, what's in store for Stage 3?

As preparations get under way for the breadth and quantity of electronic information in Stage 2 meaningful use, distinctly different challenges for HITECH Acts Stage 3 will require a provider focus on quality, quality and quality.

Health Affairs: New trial model unlocks power of personalized medicine

Oncology clinicians may soon have hundreds of biomarker tests available to them to assist in developing personalized cancer treatments, but some healthcare professionals believe that novel funding approaches for biomarker tests studiesa systematic process to move biomarker tests through regulatory agencies and a body of evidence supporting biomarker tests benefitswill all be necessary before healthcare system stakeholders accept their use.

CMS clarifies quality measurement section of healthcare reform

The Centers for Medicare & Medicaid Services (CMS) has issued a final rule regarding section 10332 of the Patient Protection and Affordable Care Act (PPACA), which allows for the release of Medicare claims data to qualified entities as a quality measurement tool, and specifically addresses the requirements organizations must meet in order to be considered a qualified entity.

JAMIA: Heterogeneous clinical databases can assist clinical association awareness

Researchers from Columbia University determined that, if examined properly, information contained in large, heterogeneous clinical databases can provide detailed illustrations of the temporal patterns of clinical associations and of the types of clinical associations that are made.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.